The Disease
Pathology
Signs & Symptoms
Risk Factors
Early Onset
Dementia
Women & Alzheimer’s
Detection
Stats & Costs
The Research
Areas of Focus
Alzheimer’s Genome Project™
Genes to Therapy / Stem Cell Screening
Identification
Immune System Structures & Processes
Interaction of the Microbiome
Pathological Pathways & Systems
Therapeutic Strategies & Drug Discovery
Whole Genome Sequencing
Other Areas of Investigation
Consortia
ALZHEIMER’S DISEASE TAU CONSORTIUM
FLEMING APOE CONSORTIUM
BRAIN ENTRY & EXIT CONSORTIUM
CIRCUITS CONSORTIUM (ENDED)
MICROBIOME CONSORTIUM
NEUROIMMUNE CONSORTIUM
Funded Projects
Grant Process
Our Researchers
Topics of Interest
Alzheimer’s in a Dish
Amyloid Hypothesis
Amyloid Precursor Protein
Brain Lymphatic System
Innate Immunity
Microglia
Blood Brain Barrier
Published Papers
Discoveries
About Us
Our Story
Our People
Reports
2023 Results
Letter from the Chair
Letter from the CEO
Letter from the Chair of RLG
Financials – Source and Use of Funds
Financials – Form 990
Audited Financials
Complete Annual Report
Research Overview
Research Areas of Focus
Funded Research Projects
Published Research Papers
Giving
Donate
Ways to Donate
Planned Giving
CRYPTOCURRENCY
Our Heroes
In Memory & In Honor
Artists Giving Back
Charity Watchdogs
News and Events
Events
2018 Symposium Video
Webinars
Interviews
Press
Videos
Research Newsletter
December 2021
Fall 2020
March 2020
November 2019
October 2019
July 2019
March 2019
January 2019
November 2018
Blog
Awareness
The Face of Alzheimer’s
Better Your Brain
World Alzheimer’s Day
Dr. Solomon Carter Fuller
Contact
781-237-3800
Donate
Contact
Search
2020 Annual Report is Now Available
Posted June 17, 2021
A PDF is available on this website here.
News
Updates
A WEBINAR WITH CRESSET CAPITAL FEATURING HENRY MCCANCE AND RUDY TANZI
Back to News and Events
Presentation To Harvard Business School Class of 1966 on Alzheimer’s Disease and Brain Health
Related Content:
Webinar: Sleep and Circadian Rhythms in Alzheimer’s Disease
Updates and Insights from Our CEO
Webinar: What’s the Role of Inflammation in Alzheimer’s disease?
What’s New In Alzheimer’s Research?
FDA APPROVES KISUNLA™ (DONANEMAB) FOR TREATMENT OF ALZHEIMER’S DISEASE
ADVISORY COMMITTEE (ADCOMM) RESULTS: DONANEMAB